# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price t...
Truist Securities analyst Asthika Goonewardene maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and maintains $17 pr...
Stifel analyst Benjamin Burnett maintains Allogene Therapeutics (NASDAQ:ALLO) with a Hold and raises the price target from $...
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of...